2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on Adjuvant Therapy in Stage III Melanoma: Is There a RFS Benefit to Adjuvant Pembrolizumab in Resected High-Risk Disease? What Is the Benefit of Dab + Tram in BRAF V600E / V600K Melanoma?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Zeynep Eroglu
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Zeynep Eroglu
Login to view comments.
Click here to Login
